The Duodenal Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Duodenal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Duodenal Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Duodenal Cancer and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Duodenal Cancer by ten companies/universities/institutes. The top development phase for Duodenal Cancer is phase ii with six drugs in that stage. The Duodenal Cancer pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Duodenal Cancer pipeline products market are: Johnson & Johnson, Genexine and Ono Pharmaceutical.
The key targets in the Duodenal Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1), and Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1).
The key mechanisms of action in the Duodenal Cancer pipeline product include Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Inhibitor with one drug in Phase II. The Duodenal Cancer pipeline products include 13 routes of administration with the top ROA being Oral and six key molecule types in the Duodenal Cancer pipeline products market including Small Molecule, and Monoclonal Antibody Conjugated.
Duodenal Cancer overview
Duodenal cancer is a type of malignancy that develops in the duodenum, which is a part of the small intestine. A malignancy involves cancerous cells that can metastasize (spread to other sites or invade and destroy nearby tissues). The most common type of duodenal cancer is adenocarcinoma.
For a complete picture of Duodenal Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
